Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zemaira versus placebo for emphysema due to alpha1-proteinase inhibitor deficiency
2005-003459-12Phase 3Completed
- Sponsor
- CSL Limited
- Start
- Oct 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in alpha-1 antitrypsin deficiency (AATD) and emphysema comparing Zemaira weekly intravenous with Placebo weekly intravenous (2 arms). Primary endpoint: Annual rate of change of lung volume-adjusted lung density estimated by P15 from CT scans. Started Oct 2005; status: completed.
02
Drugs
alpha1-proteinase inhibitor
03
Conditions
alpha-1 antitrypsin deficiency (AATD)emphysema
Beyond the preview
Go deeper on 2005-003459-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003459-12.